News
-
Het Institute for Transnational and Euregional cross border cooperation and Mobility / ITEM is per februari 2017 op zoek naar versterking van haar team in de vorm van: Stagiaire communicatie; Stagiaire 'Event organizer ITEM'; Stagiaire (1.0 fte) (Monitoring Service Grensoverschrijdende...
-
On Friday 16 December 2016 Prof. dr. Anouk Bollen-Vandenboorn accepted the unique chair ‘Cross-border Pension Tax Law’. The video of the inaugural lecture of Prof. dr. Anouk Bollen-Vandenboorn, titled 'Cross-border fiscal organisation of pensions' is now available.
-
Certain types of chemotherapy cause a greater degree of nerve damage than was previously thought (PhD conferral Tonneke Beijers).
-
The selective withdrawal of red blood cells as a treatment for haemochromatosis (iron overload) is an effective and patient-friendly alternative to phlebotomy (bloodletting) (PhD conferral Eva Rombout).
-
Alexander Hoogenboom, scientific coordinator at ITEM, is the winner of the Ius Commune Prize of 2016. Alexander Hoogenboom won the 2016 Ius Commune Prize for his paper ‘In Search of a Rationale for the EU Citizenship Jurisprudence’. The prize was awarded at the 15th Ius Commune Conference on 24...
-
Patients with metastatic breast cancer have a better life expectancy if they are treated with hormone therapy (MUMC+ news).
-
The administration of proteins during sleep is an effective way to promote muscle building (PhD conferral Bart de Groen).
-
One of the obstacles is the recognition of professional qualifications. Therefore, ITEM is announcing its intention to carry out a feasibility study about creating a “cross-border professional recognition card”. The final “cross-border professional recognition card” would be a tool developed to...
-
The Institute for Transnational and Euregional cross border cooperation and Mobility / ITEM, established in 2015, has the important objective to identify the effects of laws and regulations for border regions. Therefore ITEM launched its Cross-border impact assessment in 2016. The results of this...
-
Major subsidy for personalised treatment of degenerative joint conditions (MUMC+ News).